{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T15:33:20Z","timestamp":1793806400887,"version":"4.6.1"},"reference-count":47,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2016,1,13]],"date-time":"2016-01-13T00:00:00Z","timestamp":1452643200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,6,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:sec>\n                  <jats:title>\u2003<\/jats:title>\n                  <jats:p>Sclerostin is a potent inhibitor of osteoblastogenesis. Interestingly, newly diagnosed multiple myeloma (MM) patients have high levels of circulating sclerostin that correlate with disease stage and fractures. However, the source and impact of sclerostin in MM remains to be defined. Our goal was to determine the role of sclerostin in the biology of MM and its bone microenvironment as well as investigate the effect of targeting sclerostin with a neutralizing antibody (scl-Ab) in MM bone disease. Here we confirm increased sclerostin levels in MM compared with precursor disease states like monoclonal gammopathy of undetermined significance (MGUS) and smoldering MM. Furthermore, we found that a humanized MM xenograft mouse model bearing human MM cells (NOD-SCID.CB17 male mice injected intravenously with 2.5 million of MM1.S-Luc-GFP cells) demonstrated significantly higher concentrations of mouse-derived sclerostin, suggesting a microenvironmental source of sclerostin. Associated with the increased sclerostin levels, activated \u03b2-catenin expression levels were lower than normal in MM mouse bone marrow. Importantly, a high-affinity grade scl-Ab reversed osteolytic bone disease in this animal model. Because scl-Ab did not demonstrate significant in vitro anti-MM activity, we combined it with the proteasome inhibitor carfilzomib. Our data demonstrated that this combination therapy significantly inhibited tumor burden and improved bone disease in our in vivo MM mouse model. In agreement with our in vivo data, sclerostin expression was noted in marrow stromal cells and osteoblasts of MM patient bone marrow samples. Moreover, MM cells stimulated sclerostin expression in immature osteoblasts while inhibiting osteoblast differentiation in vitro. This was in part regulated by Dkk-1 secreted by MM cells and is a potential mechanism contributing to the osteoblast dysfunction noted in MM. Our data confirm the role of sclerostin as a potential therapeutic target in MM bone disease and provides the rationale for studying scl-Ab combined with proteasome inhibitors in MM. \u00a9 2016 American Society for Bone and Mineral Research.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1002\/jbmr.2789","type":"journal-article","created":{"date-parts":[[2016,1,14]],"date-time":"2016-01-14T03:35:29Z","timestamp":1452742529000},"page":"1225-1234","source":"Crossref","is-referenced-by-count":96,"title":["Regulation of Sclerostin Expression in Multiple Myeloma by Dkk-1: A Potential Therapeutic Strategy for Myeloma Bone Disease"],"prefix":"10.1093","volume":"31","author":[{"given":"Homare","family":"Eda","sequence":"first","affiliation":[{"name":"Massachusetts General Hospital Cancer CenterHarvard Medical SchoolBostonMAUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loredana","family":"Santo","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital Cancer CenterHarvard Medical SchoolBostonMAUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc N","family":"Wein","sequence":"additional","affiliation":[{"name":"Endocrine UnitMassachusetts General HospitalBostonMAUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorothy Z","family":"Hu","sequence":"additional","affiliation":[{"name":"Endocrine UnitMassachusetts General HospitalBostonMAUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana D","family":"Cirstea","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital Cancer CenterHarvard Medical SchoolBostonMAUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neeharika","family":"Nemani","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital Cancer CenterHarvard Medical SchoolBostonMAUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Tzu","family":"Tai","sequence":"additional","affiliation":[{"name":"LeBow Institute for Myeloma Therapeutics and Jerome Lipper Center for Multiple Myeloma Research, Dana-Farber Cancer InstituteHarvard Medical SchoolBostonMAUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah E","family":"Raines","sequence":"additional","affiliation":[{"name":"Regenerative BiologyLilly Research LaboratoriesIndianapolisINUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart Allen","family":"Kuhstoss","sequence":"additional","affiliation":[{"name":"Regenerative BiologyLilly Research LaboratoriesIndianapolisINUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikhil C","family":"Munshi","sequence":"additional","affiliation":[{"name":"LeBow Institute for Myeloma Therapeutics and Jerome Lipper Center for Multiple Myeloma Research, Dana-Farber Cancer InstituteHarvard Medical SchoolBostonMAUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry M","family":"Kronenberg","sequence":"additional","affiliation":[{"name":"Endocrine UnitMassachusetts General HospitalBostonMAUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noopur S","family":"Raje","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital Cancer CenterHarvard Medical SchoolBostonMAUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2016,1,13]]},"reference":[{"issue":"6)","key":"2024021014183432000_jbmr2789-bib-0001","doi-asserted-by":"crossref","first-page":"2962","DOI":"10.1182\/blood-2007-10-078022","article-title":"Multiple myeloma","volume":"111","author":"Kyle","year":"2008","journal-title":"Blood"},{"key":"2024021014183432000_jbmr2789-bib-0002","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1002\/(SICI)1097-0142(19971015)80:8+<1588::AID-CNCR9>3.0.CO;2-G","article-title":"Skeletal complications of malignancy","author":"Coleman","year":"1997","journal-title":"Cancer"},{"issue":"8)","key":"2024021014183432000_jbmr2789-bib-0003","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1002\/cncr.22991","article-title":"Pathologic fractures correlate with reduced survival in patients with malignant bone disease","volume":"110","author":"Saad","year":"2007","journal-title":"Cancer"},{"issue":"2)","key":"2024021014183432000_jbmr2789-bib-0004","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1002\/jcb.22403","article-title":"Pathogenesis of myeloma bone disease","volume":"109","author":"Roodman","year":"2010","journal-title":"J Cell Biochem"},{"issue":"3)","key":"2024021014183432000_jbmr2789-bib-0005","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s12307-011-0090-7","article-title":"Bone anabolic agents for the treatment of multiple myeloma","volume":"4","author":"Vallet","year":"2011","journal-title":"Cancer Microenviron"},{"issue":"4)","key":"2024021014183432000_jbmr2789-bib-0006","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1111\/j.1365-2141.1982.tb03936.x","article-title":"Quantitative histology of myeloma-induced bone changes","volume":"52","author":"Valentin-Opran","year":"1982","journal-title":"Br J Haematol"},{"issue":"12)","key":"2024021014183432000_jbmr2789-bib-0007","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1200\/JCO.1989.7.12.1909","article-title":"Mechanisms of bone destruction in multiple myeloma: the importance of an unbalanced process in determining the severity of lytic bone disease","volume":"7","author":"Bataille","year":"1989","journal-title":"J Clin Oncol"},{"issue":"13)","key":"2024021014183432000_jbmr2789-bib-0008","doi-asserted-by":"crossref","first-page":"3992","DOI":"10.1182\/blood-2006-05-026112","article-title":"Multiple myeloma bone disease: pathophysiology of osteoblast inhibition","volume":"108","author":"Giuliani","year":"2006","journal-title":"Blood"},{"issue":"6)","key":"2024021014183432000_jbmr2789-bib-0009","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1158\/1078-0432.CCR-10-1804","article-title":"Advances in the biology and treatment of bone disease in multiple myeloma","volume":"17","author":"Raje","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"11)","key":"2024021014183432000_jbmr2789-bib-0010","doi-asserted-by":"crossref","first-page":"5124","DOI":"10.1073\/pnas.0911929107","article-title":"Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease","volume":"107","author":"Vallet","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1)","key":"2024021014183432000_jbmr2789-bib-0011","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/leu.2008.259","article-title":"Bone marrow microenvironment and the identification of new targets for myeloma therapy","volume":"23","author":"Podar","year":"2009","journal-title":"Leukemia"},{"issue":"6)","key":"2024021014183432000_jbmr2789-bib-0012","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/j.bone.2008.01.027","article-title":"The pathogenesis of the bone disease of multiple myeloma","volume":"42","author":"Edwards","year":"2008","journal-title":"Bone"},{"issue":"8)","key":"2024021014183432000_jbmr2789-bib-0013","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1038\/leu.2013.50","article-title":"Lenalidomide in combination with an activin A-neutralizing antibody: preclinical rationale for a novel anti-myeloma strategy","volume":"27","author":"Scullen","year":"2013","journal-title":"Leukemia"},{"issue":"4)","key":"2024021014183432000_jbmr2789-bib-0014","doi-asserted-by":"crossref","first-page":"502","DOI":"10.6004\/jnccn.2014.0055","article-title":"Advances in supportive care for multiple myeloma","volume":"12","author":"Raje","year":"2014","journal-title":"J Natl Compr Canc Netw"},{"issue":"5)","key":"2024021014183432000_jbmr2789-bib-0015","first-page":"586","article-title":"Sotatercept, a soluble activin receptor type 2A IgG-Fc fusion protein for the treatment of anemia and bone loss","volume":"12","author":"Raje","year":"2010","journal-title":"Curr Opin Mol Ther"},{"issue":"2)","key":"2024021014183432000_jbmr2789-bib-0016","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1182\/blood-2008-11-191577","article-title":"Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma","volume":"114","author":"Fulciniti","year":"2009","journal-title":"Blood"},{"issue":"2)","key":"2024021014183432000_jbmr2789-bib-0017","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.bone.2013.01.012","article-title":"In vivo and in vitro effects of a novel anti-Dkk1 neutralizing antibody in multiple myeloma","volume":"53","author":"Pozzi","year":"2013","journal-title":"Bone"},{"issue":"6)","key":"2024021014183432000_jbmr2789-bib-0018","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1084\/jem.20031454","article-title":"Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist","volume":"199","author":"van Bezooijen","year":"2004","journal-title":"J Exp Med"},{"key":"2024021014183432000_jbmr2789-bib-0019","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.drudis.2013.04.001","article-title":"how human mutations have helped reveal a new target for the treatment of osteoporosis","author":"Robinson","year":"2013","journal-title":"Drug Discov Today"},{"issue":"2)","key":"2024021014183432000_jbmr2789-bib-0020","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1177\/1759720X13510479","article-title":"Role of sclerostin in bone and cartilage and its potential as a therapeutic target in bone diseases","volume":"6","author":"Lewiecki","year":"2014","journal-title":"Ther Adv Musculoskelet Dis"},{"issue":"20)","key":"2024021014183432000_jbmr2789-bib-0021","doi-asserted-by":"crossref","first-page":"19883","DOI":"10.1074\/jbc.M413274200","article-title":"Sclerostin binds to LRP5\/6 and antagonizes canonical Wnt signaling","volume":"280","author":"Li","year":"2005","journal-title":"J Biol Chem"},{"issue":"4)","key":"2024021014183432000_jbmr2789-bib-0022","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1517\/14728220902841961","article-title":"Wnt signaling as a therapeutic target for bone diseases","volume":"13","author":"Hoeppner","year":"2009","journal-title":"Expert Opin Ther Targets"},{"issue":"11)","key":"2024021014183432000_jbmr2789-bib-0023","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1038\/nrrheum.2011.130","article-title":"New targets for intervention in the treatment of postmenopausal osteoporosis","volume":"7","author":"Lewiecki","year":"2011","journal-title":"Nat Rev Rheumatol"},{"issue":"4)","key":"2024021014183432000_jbmr2789-bib-0024","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1359\/jbmr.081206","article-title":"Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis","volume":"24","author":"Li","year":"2009","journal-title":"J Bone Miner Res"},{"issue":"6)","key":"2024021014183432000_jbmr2789-bib-0025","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1002\/ijc.27342","article-title":"Elevated circulating sclerostin correlates with advanced disease features and abnormal bone remodeling in symptomatic myeloma: reduction post-bortezomib monotherapy","volume":"131","author":"Terpos","year":"2012","journal-title":"Int J Cancer"},{"issue":"6)","key":"2024021014183432000_jbmr2789-bib-0026","doi-asserted-by":"crossref","first-page":"e27","DOI":"10.1038\/bcj.2011.22","article-title":"Myeloma cells suppress osteoblasts through sclerostin secretion","volume":"1","author":"Colucci","year":"2011","journal-title":"Blood Cancer J"},{"key":"2024021014183432000_jbmr2789-bib-0027","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/j.1749-6632.2011.06196.x","article-title":"Sclerostin is overexpressed by plasma cells from multiple myeloma patients","volume":"1237","author":"Brunetti","year":"2011","journal-title":"Ann N Y Acad Sci"},{"issue":"3)","key":"2024021014183432000_jbmr2789-bib-0028","first-page":"266","article-title":"Osteogenic inhibition in multiple myeloma","volume":"15","author":"Habibi","year":"2013","journal-title":"Cell J"},{"issue":"11)","key":"2024021014183432000_jbmr2789-bib-0029","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1182\/blood-2011-10-387365","article-title":"Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma","volume":"119","author":"Santo","year":"2012","journal-title":"Blood"},{"issue":"9)","key":"2024021014183432000_jbmr2789-bib-0030","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1038\/leu.2014.69","article-title":"A novel Bruton's tyrosine kinase inhibitor CC-292 in combination with the proteasome inhibitor carfilzomib impacts the bone microenvironment in a multiple myeloma model with resultant antimyeloma activity","volume":"28","author":"Eda","year":"2014","journal-title":"Leukemia"},{"issue":"9)","key":"2024021014183432000_jbmr2789-bib-0031","doi-asserted-by":"crossref","first-page":"3281","DOI":"10.1182\/blood-2007-01-065888","article-title":"Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma","volume":"110","author":"Kuhn","year":"2007","journal-title":"Blood"},{"issue":"5)","key":"2024021014183432000_jbmr2789-bib-0032","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.clml.2012.08.003","article-title":"An open-label single-arm pilot phase II study (PX-171-003-A0) of low-dose, single-agent carfilzomib in patients with relapsed and refractory multiple myeloma","volume":"12","author":"Jagannath","year":"2012","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"14)","key":"2024021014183432000_jbmr2789-bib-0033","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1182\/blood-2012-05-425934","article-title":"A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma","volume":"120","author":"Siegel","year":"2012","journal-title":"Blood"},{"issue":"2)","key":"2024021014183432000_jbmr2789-bib-0034","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/leu.2012.183","article-title":"The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects","volume":"27","author":"Hurchla","year":"2013","journal-title":"Leukemia"},{"issue":"8)","key":"2024021014183432000_jbmr2789-bib-0035","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1038\/leu.2013.29","article-title":"Carfilzomib in multiple myeloma patients with renal impairment: pharmacokinetics and safety","volume":"27","author":"Badros","year":"2013","journal-title":"Leukemia"},{"issue":"12)","key":"2024021014183432000_jbmr2789-bib-0036","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1038\/leu.2013.152","article-title":"Treatment outcomes in patients with relapsed and refractory multiple myeloma and high-risk cytogenetics receiving single-agent carfilzomib in the PX-171-003-A1 study","volume":"27","author":"Jakubowiak","year":"2013","journal-title":"Leukemia"},{"issue":"5)","key":"2024021014183432000_jbmr2789-bib-0037","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1038\/leu.2008.378","article-title":"Preclinical activity of P276-00, a novel small-molecule cyclin-dependent kinase inhibitor in the therapy of multiple myeloma","volume":"23","author":"Raje","year":"2009","journal-title":"Leukemia"},{"issue":"2)","key":"2024021014183432000_jbmr2789-bib-0038","first-page":"491","article-title":"Pharmacologic targeting of a stem\/progenitor population in vivo is associated with enhanced bone regeneration in mice","volume":"118","author":"Mukherjee","year":"2008","journal-title":"J Clin Invest"},{"issue":"7)","key":"2024021014183432000_jbmr2789-bib-0039","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1002\/jbmr.141","article-title":"Guidelines for assessment of bone microstructure in rodents using micro-computed tomography","volume":"25","author":"Bouxsein","year":"2010","journal-title":"J Bone Miner Res"},{"issue":"23)","key":"2024021014183432000_jbmr2789-bib-0040","doi-asserted-by":"crossref","first-page":"6267","DOI":"10.1093\/emboj\/cdg599","article-title":"Osteocyte control of bone formation via sclerostin, a novel BMP antagonist","volume":"22","author":"Winkler","year":"2003","journal-title":"EMBO J"},{"issue":"13)","key":"2024021014183432000_jbmr2789-bib-0041","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1096\/fj.05-4221fje","article-title":"Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation","volume":"19","author":"Poole","year":"2005","journal-title":"FASEB J"},{"issue":"6)","key":"2024021014183432000_jbmr2789-bib-0042","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1038\/leu.2011.381","article-title":"Increased osteocyte death in multiple myeloma patients: role in myeloma-induced osteoclast formation","volume":"26","author":"Giuliani","year":"2012","journal-title":"Leukemia"},{"issue":"9429)","key":"2024021014183432000_jbmr2789-bib-0043","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S0140-6736(04)16627-0","article-title":"Investigation of multipotent postnatal stem cells from human periodontal ligament","volume":"364","author":"Seo","year":"2004","journal-title":"Lancet"},{"issue":"4)","key":"2024021014183432000_jbmr2789-bib-0044","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1359\/jbmr.2003.18.4.696","article-title":"Perivascular niche of postnatal mesenchymal stem cells in human bone marrow and dental pulp","volume":"18","author":"Shi","year":"2003","journal-title":"J Bone Miner Res"},{"issue":"1)","key":"2024021014183432000_jbmr2789-bib-0045","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0092-8674(01)00622-5","article-title":"The novel zinc finger-containing transcription factor osterix is required for osteoblast differentiation and bone formation","volume":"108","author":"Nakashima","year":"2002","journal-title":"Cell"},{"issue":"12)","key":"2024021014183432000_jbmr2789-bib-0046","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1136\/ard.2010.132852","article-title":"Neutralisation of Dkk-1 protects from systemic bone loss during inflammation and reduces sclerostin expression","volume":"69","author":"Heiland","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"26)","key":"2024021014183432000_jbmr2789-bib-0047","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1056\/NEJMoa030847","article-title":"The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma","volume":"349","author":"Tian","year":"2003","journal-title":"N Engl J Med"}],"container-title":["Journal of Bone and Mineral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjbmr.2789","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/31\/6\/1225\/56649865\/jbmr2789.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/31\/6\/1225\/56649865\/jbmr2789.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T14:55:47Z","timestamp":1710341747000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmr\/article\/31\/6\/1225-1234\/7605248"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1,13]]},"references-count":47,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2016,1,13]]},"published-print":{"date-parts":[[2016,6,1]]}},"URL":"https:\/\/doi.org\/10.1002\/jbmr.2789","relation":{},"ISSN":["0884-0431","1523-4681"],"issn-type":[{"value":"0884-0431","type":"print"},{"value":"1523-4681","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2016,6,1]]},"published":{"date-parts":[[2016,1,13]]}}}